Pharmaceutical science communication is the tool by which a pharma or biotech company translates the complexity of science into clear, credible, and visually powerful messages–to clinicians, payers, investors, and patients. View Science produces 3D scientific videos, mechanism-of-action animations, infographics, and graphic materials designed with scientific rigor and visual impact, integrating this capability with regulatory and market access consulting to ensure message consistency throughout the product lifecycle.
A drug acts at the molecular, cellular, systemic level: processes that no words or static images can convey as effectively as a 3D scientific video. View Science creates high-fidelity scientific pharmaceutical animations for the main use cases of pharma communication: conference presentations, sales representative materials, HTA negotiation videos, digital content for medical/scientific campaigns, and in-house training.
The formats we produce:
Each project starts with a scientific briefing: we work closely with your medical/scientific or regulatory team to ensure that each animation is accurate, conforms to EMA guidelines, and is consistent with the claims approved in the registration dossier.
Next to videos, pharma visual communication requires an arsenal of static and semi-animated graphic materials: presentations for medical congresses, scientific posters, infographics for HTA value communication, materials for ISF, slide decks for investor relations. View Science designs these materials with an approach that integrates professional graphic design and scientific accuracy-two skills rarely found in the same firm.
The portfolio of scientific and pharmaceutical graphics includes:
Most science communication agencies are separate from the regulatory world. Most regulatory consultancies do not have an in-house creative department. View Science is the convergence point: we produce science communication knowing the dossier, the HTA, the regulatory strategy. This eliminates the risks of misalignment between communicative claims and approved claims, reduces review cycles, and ensures ready-made materials for use in negotiations with payers and health authorities.
According to research published in Frontiers in Digital Health, animated videos significantly improve understanding of complex scientific information compared to traditional text-based formats-both among HCPs and patients. For pharma companies, this translates into a measurable benefit: more informed HCPs, payers better oriented to product value, patients more adherent to therapy.
We work with Pharmaceutical Companies of all sizes – from biotech SMEs to the Italian subsidiary of a multinational company – adapting the level of production, format and budget to the specific needs of the project. You can entrust us with the production of a single MoA video as well as an entire 360° scientific communication plan. See also our Regulatory Affairs and Market Access and HTA pages to find out how we integrate all services.
Do you have an action mechanism to visualize, an upcoming conference, or a campaign to support? Ask us for a free quote – we will show you examples from our portfolio and define together the format, timing and budget for your science communication project.
Alessandro is a professional with over 35 years of experience in the pharmaceutical and biotech industry, gained through roles of increasing responsibility in areas such as marketing, medical affairs, outcomes research, health economics, value access, and HTA. He has worked with major international companies including Merck Sharp & Dohme, Sanofi-Pasteur, Baxter, Baxalta-Shire and Organon. He has strong expertise in pricing and reimbursement processes, with 28 successfully completed procedures in several European countries (UK, Italy, France and Spain). Throughout his career, he has designed and implemented high-impact programs to demonstrate the clinical and economic value, sustainability, and effectiveness of new healthcare solutions. He combines his professional activities with international academic collaboration, particularly with UK university centers, and is currently an external member of the Statistics for Health Economic Evaluation Group at University College London. He also has a wide network of professional contacts that includes key European public decision makers and has contributed numerous publications in scientific and health economics journals.
Giovanni is a leading international expert in the field of advanced therapies, with consolidated experience in regulatory aspects related to the use of cultured cells for clinical applications and in cell and gene therapies. He works as an expert for the Italian Government and the European Medicines Agency (EMA) and was Chair of the CTP group at the European Directorate for the Quality of Medicines (EDQM) from 2010 to 2018. He currently serves as Scientific Director of the TEDDY network (Bari 2026), Regulatory Advisor for the Center for Biological and Pharmacological Evaluations (CVBF, Pavia), and Senior Advisor for the European EATRIS infrastructure. He holds a PhD in Biological Sciences from the University of Naples and has developed his scientific career in the study of mechanisms of stem cell proliferation and differentiation, with research experience in the United States and at the Istituto Superiore di Sanità, contributing more than 200 scientific publications.
Ludovica is a Senior Leader with more than 30 years of experience in the life sciences sector, with a strong results orientation and an established ability to translate scientific research into accessible therapeutic solutions. He has gained significant experience in the area of market access, successfully contributing to processes of drug enhancement and availability for patients. Throughout his career he has built a wide institutional network, actively collaborating with public stakeholders and policy makers. He also has strong expertise in Price and Reimbursement negotiations with Italian regulatory authorities, working in multiple therapeutic areas including chronic non-communicable diseases, oncology, hematology, virology and rare diseases. In parallel, she is active as a business angel in the evaluation and support of innovative startups.
Fabrizio is a professional with scientific background, Founder and currently CEO of ViewScience. His education is developed in the field of biotechnology, with a bachelor’s and a master’s degree in Medical Biotechnology at the University of Rome “Tor Vergata,” followed by a Master’s degree in clinical and preclinical drug development at the Catholic University of the Sacred Heart, with focus on technical-scientific, regulatory and ethical aspects. During his career, he has gained expertise in regulatory affairs and pharmaceutical consulting, working alongside companies in product enhancement from a strategic point of view and in scientific communication.
